ClinicalTrials.gg
RecruitingNCT07199465Updated Oct 30, 2026

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

A Phase 1 interventional study of Letermovir in Cytomegalovirus Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Recruiting at 22 sites in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 30, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to:

  • Learn what happens to letermovir in the body over time
  • Learn about the safety of letermovir and if participants tolerate it
02

Conditions studied

  • Cytomegalovirus Prophylaxis
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is a recipient of a primary or secondary allograft kidney
  • Is at least 4 weeks posttransplant and not more than 52 weeks posttransplant at the time of enrollment (Day 1) and is being managed per local standard of care
  • Has stable kidney function posttransplant
  • Has undetectable CMV deoxyribonucleic acid (DNA) from a plasma or whole blood sample collected within 14 days prior to enrollment
  • Must be able to take (as assessed by the investigator) letermovir tablets or oral pellets by mouth, or via gastrostomy or nasogastric tube (oral pellets only)
  • Does not have a condition that may interfere with the absorption of oral medication (e.g., vomiting, diarrhea, or a malabsorptive condition) from the day of enrollment (Day 1) until the intensive pharmacokinetics (IPK) sampling is completed
  • Weighs ≥2.5 and \<40 kg at enrollment (Day 1)

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has CMV disease or suspected CMV disease between screening and enrollment
  • Is on dialysis or plasmapheresis at the time of enrollment
  • Has evidence of CMV viremia at any time from screening until the time of enrollment
  • Has B or C hepatic insufficiency within 14 days before enrollment
  • Is a multi-organ transplant recipient (e.g., kidney-pancreas)
  • Has any uncontrolled infection on the day of enrollment
  • Requires mechanical ventilation, or is hemodynamically unstable, at the time of enrollment
  • Has received or is receiving protocol-specified prohibited medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Weight-banded letermovir dosing

    Participants who are between 4 and 52 weeks post-KT will receive letermovir for 7 consecutive days.

    Drug: Letermovir

Interventions

  • Administered orally (as tablets/pellets) or via gastrostomy or nasogastric tube (as pellets) for 7 consecutive days.

    Also known as: MK-8228, AIC246, AIC001, PREVYMIS™

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time 0 to 24 Hours (AUC0-24)

    Blood samples will be collected at multiple time points to estimate AUC0-24

    Time frame: Day 7: Predose and at designated timepoints post-dose (up to 24 hours)

Secondary outcomes

  1. Percentage of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.

    Time frame: Up to 21 days

  2. Percentage of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.

    Time frame: Up to 7 days

07

Study locations

22 of 22 sites recruiting
  • University of Alabama at Birmingham - School of Medicine - Pediatrics ( Site 0019)
    Birmingham, Alabama 35233, United States
    Recruiting
    • Study Coordinator · Contact205-638-9781
  • Children's Hospital Los Angeles ( Site 0016)
    Los Angeles, California 90027, United States
    Recruiting
    • Study Coordinator · Contact323-660-2450
  • UCLA Clinical & Translational Research Center (CTRC) ( Site 0006)
    Los Angeles, California 90095, United States
    Recruiting
    • Study Coordinator · Contact310-825-5225
  • Lucile Packard Children's Hospital ( Site 0001)
    Palo Alto, California 94304, United States
    Recruiting
    • Study Coordinator · Contact408-828-5120
  • University of California Davis Health ( Site 0023)
    Sacramento, California 95817, United States
    Recruiting
    • Study Coordinator · Contact916-734-8036
  • UCSF Medical Center at Mission Bay ( Site 0017)
    San Francisco, California 94158, United States
    Recruiting
    • Study Coordinator · Contact415-347-1885
  • Children's Hospital Colorado ( Site 0013)
    Aurora, Colorado 80045, United States
    Recruiting
    • Study Coordinator · Contact720-777-6263
  • University of Miami School of Medicine ( Site 0021)
    Miami, Florida 33136, United States
    Recruiting
    • Study Coordinator · Contact305-243-4445
  • Children's Healthcare of Atlanta-Center for Advanced Pediatrics ( Site 0020)
    Atlanta, Georgia 30329, United States
    Recruiting
    • Study Coordinator · Contact404-785-5437
  • Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0004)
    Chicago, Illinois 60611, United States
    Recruiting
    • Study Coordinator · Contact312-227-2061
  • University of Michigan ( Site 0014)
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Study Coordinator · Contact734-936-6280
  • M Health Fairview University of Minnesota Masonic Children's Hospital, West Bank ( Site 0007)
    Minneapolis, Minnesota 55454, United States
    Recruiting
    • Study Coordinator · Contact612-365-0013
  • Mayo Clinic - Rochester ( Site 0015)
    Rochester, Minnesota 55905, United States
    Recruiting
    • Study Coordinator · Contact507-254-1714
  • Morgan Stanley Children's Hospital ( Site 0018)
    New York, New York 10032, United States
    Recruiting
    • Study Coordinator · Contact212-305-2500
  • Montefiore Medical Center ( Site 0024)
    The Bronx, New York 10467, United States
    Recruiting
    • Study Coordinator · Contact718-741-2426
  • Levine Children's Hospital ( Site 0022)
    Charlotte, North Carolina 28203, United States
    Recruiting
    • Study Coordinator · Contact704-446-4842
  • Duke University-Pediatrics ( Site 0008)
    Durham, North Carolina 27710, United States
    Recruiting
    • Study Coordinator · Contact919-684-6335
  • Cincinnati Children's Hospital Medical Center ( Site 0002)
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Study Coordinator · Contact513-636-3017
  • Children's Hospital of Philadelphia (CHOP) ( Site 0003)
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Study Coordinator · Contact215-590-1000
  • Children's Hospital of Pittsburgh - Department of Pediatrics ( Site 0011)
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Study Coordinator · Contact412-864-6893
  • Texas Children's Hospital ( Site 0005)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact832-824-4330
  • University of Wisconsin ( Site 0012)
    Madison, Wisconsin 53792, United States
    Recruiting
    • Study Coordinator · Contact608-264-1400
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 30, 2025
StartActual
Mar 30, 2026
Primary completionEst.
Apr 14, 2028
CompletionEst.
May 19, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University of Wisconsin ( Site 0012) · Madison, United States
Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    1 site added
    Show site
    • University of Wisconsin ( Site 0012) · Madison, United States
  2. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07199465
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Mar 30, 2026
Primary completion
Apr 14, 2028 (estimated)
Completion
May 19, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion